Please login to the form below

Not currently logged in
Email:
Password:

glaucoma

This page shows the latest glaucoma news and features for those working in and with pharma, biotech and healthcare.

FDA’s year-end approvals take annual tally to 46

FDA’s year-end approvals take annual tally to 46

The traditional late flurry of approvals was a bit smaller this year, but included Aerie Pharma’s Rhopressa (netarsudil), a once-daily drug for open-angle glaucoma and ocular hypertension that ... Next year, it hopes to add a second glaucoma drug to

Latest news

  • Mallinckrodt pays $1.2bn for Sucampo Pharma Mallinckrodt pays $1.2bn for Sucampo Pharma

    Mallinckrodt is paying $18 per share for Sucampo and will also assume the company’s $360m debt under the terms of the deal, adding Amitizia (lubiprostone), glaucoma treatment Rescula (unoprostone isopropyl)

  • The conundrum of screening The conundrum of screening

    Good examples of screening programmes where the early detection, diagnosis and treatment have favourable outcomes are glaucoma, hypertension and breast cancer, to name a few.

  • FDA approves wireless contact lens sensor FDA approves wireless contact lens sensor

    optic nerve damage characteristic of glaucoma. ... Glaucoma is a leading cause of vision loss and affects an estimated three million people in the US with many suffering no symptoms until significant and irreversible vision loss.

  • Allergan backs new glaucoma app Allergan backs new glaucoma app

    Allergan backs new glaucoma app. GlaucomaIn Perspective was developed by City University London. ... An estimated half a million people in the UK are living with undiagnosed glaucoma.

  • Trial suggests Sanofi's asthma drug works in sinusitis Trial suggests Sanofi's asthma drug works in sinusitis

    They are generally being positioned as steroid-sparing agents, which is desirable as the latter drugs can have side effects such as weight gain, diabetes, high blood pressure and glaucoma, and

More from news
Approximately 3 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    For example, Allergan has acquired ForSight Visions, a company that has developed a peri-ocular device that allows extended release of a drug to reduce intra-ocular pressure in glaucoma patients. ... 105. ForSight Visions. Allergan. Company acquisition.

  • Digital Business Models Digital Business Models

    For example, a pressure sensor in a smart contact lens monitors and controls intra-ocular pressure levels as well as identifies early cases of glaucoma.

  • Pharma deals in September 2015 Pharma deals in September 2015

    Acquisition - product. 445. Aquesys. Allergan. Implantable shunt for glaucoma. Acquisition - company.

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    R&D focus is on discovering new treatments for conditions including age-related macular degeneration (AMD), eye allergies, infections, inflammation, dry eye, glaucoma, cataract and refractive errors.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • ThromboGenics bolsters leadership team ThromboGenics bolsters leadership team

    Schneider has 16 years’experience of clinical drug development and prior to her new role, she most recently served Allergan as its vice president and therapeutic head of retina and glaucoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics